Email this article MYELOID-DERIVED SUPPRESSOR CELLS IN MULTIPLE MYELOMA PATIENTSDURING THE MOBILIZATION OF HEMATOPOETIC STEM CELLS
- Authors: Aristova T.A.1, Batorov E.V.1, Ostanin A.A.1
-
Affiliations:
- Federal Budget Institution of Science «Research Institute of Fundamental and Clinical Immunology»
- Issue: Vol 22, No 2-1 (2019)
- Pages: 142-143
- Section: ORIGINAL ARTICLES
- Submitted: 03.04.2020
- Accepted: 03.04.2020
- Published: 15.04.2019
- URL: https://rusimmun.ru/jour/article/view/24
- DOI: https://doi.org/10.31857/S102872210006429-6
- ID: 24
Cite item
Full Text
Abstract
We investigated the relative content of circulating early (Lin–CD33+HLA-DR–CD66b–), granulocyte (Lin–CD33+HLA-DR–CD66b+) and monocyte (CD14+HLA-DRlow/–) myeloid-derived suppressor cells (MDSCs) in patients with primary multiple myeloma (MM) at the mobilization of hematopoietic stem cells (HSC). The relative count of all the studied subtypes of MDSCs in patients with both complete remission and partial response did not significantly differ from those in healthy donors. Mobilization of HSCs was not associated with any changes in the content of CD14+HLA-DRlow/– and Lin–CD33+HLADR–CD66b–, however, led to a significant increase in Lin–CD33+HLA-DR–CD66b+. Thus, carrying out the mobilization of HSCs in patients with MM maybe accompanied by the accumulation of granulocyte MDSCs in the autograft.
About the authors
T. A. Aristova
Federal Budget Institution of Science «Research Institute of Fundamental and Clinical Immunology»
Author for correspondence.
Email: ct_lab@mail.ru
postgraduate student,
Novosibirsk
Russian FederationE. V. Batorov
Federal Budget Institution of Science «Research Institute of Fundamental and Clinical Immunology»
Email: fake@neicon.ru
PhD, Researcher,
Novosibirsk
Russian FederationA. A. Ostanin
Federal Budget Institution of Science «Research Institute of Fundamental and Clinical Immunology»
Email: fake@neicon.ru
MD, Chief Researcher,
Novosibirsk
Russian FederationReferences
- Betsch A., Rutgeerts O., Fevery S., Sprangers B., Verhoef G., Dierickx D., Beckers M. Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.//Blood Rev. 2018. pii: S0268–960X(17)30092–9.
- Khalifa K. A., Badawy H. M., Radwan W. M., Shehata M. A., Bassuoni M. A. CD14(+) HLA-DR low/(–) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int J Lab Hematol. 2014,36(6), 650–5.
- Marini O., Spina C., Mimiola E., Cassaro A., Malerba G., Todeschini G., Perbellini O., Scupoli M., Carli G., Facchinelli D., Cassatella M., Scapini P., Tecchio C. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016, 7(19), 27676–88.
- Romano A., Parrinello N. L., Vetro C., Forte S., Chiarenza A., Figuera A., Motta G., Palumbo G. A., Ippolito M., Consoli U., Di Raimondo F. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015,168(5), 689–700.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).